VaramirStart free · no cardSign in
BEAM as of Oct 31 · 21:08 ET
BEAMNasdaqBiological Products, (No Diagnostic Substances)

Beam Therapeutics Inc. · Brief

Next report

2 days

Nov 3 · before openest.Q3 FY26
Earnings

Expected move

Inputs

Implied vs realized

8 reportsHistory
1 of 7≥ implied
avg implied
±14.0%
avg realized
±8.1%
Nov 5 '24—▼−1.77%—
Feb 25 '25±18.5%▼−3.09%×0.17
May 6 '25±11.8%▼−19.32%×1.63
Aug 5 '25±14.3%▼−2.20%×0.15
Q3 FY25±11.8%▼−6.23%×0.53
Q1 FY26±19.4%▲+13.98%×0.72
May 7 '26±9.2%▼−2.69%×0.29
Q2 FY26±13.3%▲+9.42%×0.71
quarterimplied−20%0+20%realized×
Q2 FY26±13.3%▲+9.42%×0.71
May '26±9.2%▼−2.69%×0.29
Q1 FY26±19.4%▲+13.98%×0.72
Q3 FY25±11.8%▼−6.23%×0.53
Aug '25±14.3%▼−2.20%×0.15
May '25±11.8%▼−19.32%×1.63
2 older reports
Feb '25±18.5%▼−3.09%×0.17
Nov '24—▼−1.77%—
Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Nov 3 report · est.

Bull2 of 3

10disclosed supplier and customer ties in SEC filingsSEC filings
6tracked funds holding BEAMN-PORT · Aug 31 '26

Bear2

6 of 7recent reports where the move came in under the options implied rangeEarnings history
6 of 24largest reporting managers who cut their stake in the latest quarter13F · Jun 30 '26
AI captions · Sep 28 '26once per report · top 2 per case

Linked exposure

BEAM report session

Suppliers 2

PRMEPrime Medicine×0.81EDITEditas Medicine×0.76

Customers 2

SANASana Biotechnology×0.62PFEPfizer×0.08
× = co-movement · max 500dSource: SEC filings · market data

Latest changes

30 daysAll changes
Oct 20impliedImplied move: ±13.0% into Nov 3 earnings (Oct 20 close).Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.